Last reviewed · How we verify
FS MDPI
FS MDPI is a monoamine oxidase inhibitor that increases levels of dopamine, norepinephrine, and serotonin in the central nervous system.
FS MDPI is a monoamine oxidase inhibitor that increases levels of dopamine, norepinephrine, and serotonin in the central nervous system. Used for Major depressive disorder.
At a glance
| Generic name | FS MDPI |
|---|---|
| Also known as | fluticasone propionate, inhaled corticosteroid, Salmeterol xinafoate, β2 adrenoceptor agonist, FS Spiromax |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Monoamine oxidase inhibitor (MAOI) |
| Target | Monoamine oxidase |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting monoamine oxidase, FS MDPI prevents the breakdown of key neurotransmitters, leading to their accumulation in synaptic spaces. This mechanism is intended to enhance mood regulation and cognitive function. The drug is being developed for neuropsychiatric indications where monoamine deficiency is implicated.
Approved indications
- Major depressive disorder
Common side effects
- Hypertensive crisis (with tyramine-containing foods)
- Orthostatic hypotension
- Insomnia
- Headache
Key clinical trials
- Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older (PHASE1)
- Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (PHASE3)
- Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma (PHASE3)
- A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma (PHASE1)
- Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FS MDPI CI brief — competitive landscape report
- FS MDPI updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI